Two previously-unknown mutations in the CLN5 gene were reported to cause CLN5 disease, a form of late infantile…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Amicus Therapeutics‘ AT-GTX-502, an investigational…
Polaryx Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) to open a clinical trial…
An investigational gene therapy for late infantile (CLN2) Batten disease showed a good safety profile in a small clinical trial.